Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey

Eur J Breast Health 2016;12(3):107-111

DOI: 10.5152/tjbh.2016.2874

1. Department of General Surgery, İstanbul University İstanbul School of Medicine, İstanbul, Turkey

2. Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, İstanbul, Turkey

3. Division of Medical Oncology, Department of Internal Medicine, Ege University School of Medicine, İzmir, Turkey

4. Division of Medical Oncology, Department of Internal Medicine, Akdeniz University School of Medicine, Antalya, Turkey

5. Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Institute of Oncology, Ankara, Turkey

6. Department of General Surgery, Acıbadem University, İstanbul, Turkey

7. Department of General Surgery, Erciyes University School of Medicine, Kayseri, Turkey

8. Department of General Surgery, Çukurova University School of Medicine, Adana, Turkey

9. Division of Medical Oncology, Department of Internal Medicine, Dicle University School of Medicine, Diyarbakır, Turkey

10. Department of Medicine, Division of Medical Oncology, İstanbul University Institute of Oncology, İstanbul, Turkey

11. Clinic of Internal Medicine, Antalya Memorial Hospital, Antalya, Turkey

12. Department of General Surgery, Acıbadem University, İstanbul, Turkey

No information available.

No information available

Received Date: 30.11.2015

Accepted Date: 05.04.2016

PDF

Cite

Request

ABSTRACT

Objective:

Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the correlations between Recurrence Score (RS) and routine risk factors.

Materials and Methods:

Ten academic centers across Turkey participated in this prospective trial. Consecutive patients with breast cancer who had pT1-3, pN0-N1mic, ER-positive, and HER2-negative tumors were identified at tumor conferences. Both pre- and post-RS treatment decisions and physician perceptions were recorded on questionnaire forms. Correlations between RS and classic risk factors were evaluated using univariate and multivariate analyses.

Results:

Ten centers enrolled a total of 165 patients. The median tumor size was 2 cm. Of the 165 patients, 57% had low RS, 35% had intermediate RS, and 8% had high RS, respectively. Multivariate analysis indicated that progesterone receptor (PR) and Ki67 scores were significantly related to RS.

Conclusion:

Oncotype DX Recurrence Score does not seem to have a significant correlation with the majority of classic risk factors, but it may have a correlation with PR score and Ki67 score.